Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IDEXX Laboratories, Inc. (IDXX) vs Wipro Limited (WIT) Price & Performance

IDEXX Laboratories, Inc.Trade
Wipro LimitedTrade

Price performance (Past 24H)

Key statistics

IDEXX Laboratories, Inc. vs Wipro Limited — how do they compare? IDEXX Laboratories, Inc. trades at $586.65 (market cap $46.93B), while Wipro Limited trades at $1.98 (market cap $19.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.4× Wipro Limited's market cap, and Wipro Limited pays a 4.35% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.

IDXXWIT
Market Cap
$46.93B$19.22B
Sector
HealthTechnology
52-Week High
$766.68$3.06
52-Week Low
$526.44$1.78
Enterprise Value
$47.83B$17.30B
Dividend Yield
4.35%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IDEXX Laboratories, Inc.

IDEXX Laboratories trades at $586.67, down 0.56% on the day, with strong technical momentum showing bullish moving averages and key resistance at $590. The company demonstrates robust fundamentals with Q2 2026 EPS of $4.27 beating estimates by 8.4% and full-year guidance raised to $14.69-14.94. Revenue growth accelerated to 10% year-over-year, supported by 9% organic growth in companion animal diagnostics. Net income margin expanded to 25.03% with exceptional ROE of 74.21%, though valuation multiples remain elevated at P/E 41.23.

Outlook remains positive with analyst consensus at 56.5% buy ratings, though premium valuation and competitive pressures present risks. The stock's technical setup suggests potential breakout above $590 resistance could target $609-618 levels, while support at $578-570 provides downside protection. Continued execution on international expansion and diagnostic adoption supports growth trajectory.

Wipro Limited

WIT trades at $2.02, up 1.51% today, with a neutral technical signal and bearish moving average trend. The company reported a net income margin of 13.92% and ROE of 16.09% for 2025, with revenue of $890.88 billion. Recent earnings have missed expectations, but partnerships with Databricks and ServiceNow aim to drive AI-led growth. Cash flow from operations remains strong at $169.43 billion, supporting a $0.02 dividend.

The outlook is mixed: valuation ratios like P/E of 15.25 and EV/EBITDA of 7.83 appear reasonable, but earnings misses and competitive pressures pose risks. Analyst sentiment is cautious with only 19% buy ratings. Key opportunities include AI expansion, while risks involve client spending cuts and margin pressure from wage increases.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX

About Wipro Limited

Wipro is a leading global IT services provider, with 175,000 employees. Based in Bengaluru, this India IT services firm leverages its offshore outsourcing model to derive over half of its revenue (57%) from North America. The company offers traditional IT services offerings: consulting, managed services, and cloud infrastructure services as well as business process outsourcing as a service.

Read more on WIT